Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaeal1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:59:22 ON 06 MAR 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:59:29 ON 06 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2008 HIGHEST RN 1006749-26-3
DICTIONARY FILE UPDATES: 5 MAR 2008 HIGHEST RN 1006749-26-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560119.str





chain nodes :
7 8 11 12 13 14 15 16 22 24 25 27
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
9 10
chain bonds :
2-7 5-8 8-9 8-15 8-16 9-10 9-25 9-27 10-11 10-22 10-24 11-12 11-14 12-13

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6 5-8 8-9 8-15 8-16 9-25 9-27 10-22 10-24 11-12 11-14 12-13
exact bonds :
9-10 10-11
isolated ring systems :
containing 1 :

G1:Cy,Ak

G2:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 22:CLASS 24:CLASS 25:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 16:59:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 188 TO ITERATE

100.0% PROCESSED 188 ITERATIONS 52 ANSWERS
SEARCH TIME: 00.00.01

L2 52 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 16:59:53 ON 06 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Mar 2008 VOL 148 ISS 10
FILE LAST UPDATED: 5 Mar 2008 (20080305/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l2 full
L3            5 L2

=> d ibib abs hitstr tot

L3   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:1154688  CAPLUS  Full-text
DOCUMENT NUMBER:          142:93854
TITLE:                    A preparation of N-hydroxy-
                          (piperazinylsulfonyl)alkanoic acid amide derivatives,
                          useful as CD23 shedding inhibitors
INVENTOR(S):              Owen, David Alan; Watson, Robert John; Allen, Daniel
                          Rees; Sharpe, Andrew; Dyke, Hazel Joan
PATENT ASSIGNEE(S):       Celltech R & D Limited, UK
SOURCE:                   PCT Int. Appl., 53 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
     WO 2004113312        A1    20041229    WO 2004-GB2638           20040618
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004249496        A1    20041229    AU 2004-249496           20040618
     CA 2528317           A1    20041229    CA 2004-2528317          20040618
     EP 1641771           A1    20060405    EP 2004-742991           20040618
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     JP 2006527754         T    20061207    JP 2006-516449           20040618
     US 2006241118        A1    20061026    US 2006-560119           20060517
PRIORITY APPLN. INFO.:                      GB 2003-14244        A   20030619
                                            GB 2003-25834        A   20031105
                                            WO 2004-GB2638       W   20040618
OTHER SOURCE(S):          MARPAT 142:93854
GI
```



I



II

AB The invention relates to a preparation of (piperazinylsulfonyl)alkanoic acid amide derivs. of formula I [wherein: Cy is (hetero)aryl; X is (CH2)0-3; Y is (CH2)1-3; R1 is (cyclo)alkyl, (hetero)aryl, or alkylcycloalkyl, etc.; R2 is H or alkyl; R3 and R4 are independently selected from F, Cl, Br, or haloalkyl, etc.; R5 is alkyl; R6 is H or alkyl], useful as CD23 shedding inhibitors (no biol. data). For instance, N-hydroxy- (piperazinylsulfonylmethyl)butyramide derivative II was prepared via amination of 2-chlorosulfonylmethyl-3-methylbutyric acid tert-Bu ester by 1-o-tolylpiperazine and subsequent amidation of the obtained ester by NH2OH.

IT 817170-72-2P 817170-73-3P 817170-74-4P
817170-75-5P 817170-76-6P 817170-77-7P
817170-78-8P 817170-79-9P 817170-80-2P
817170-81-3P 817170-82-4P 817170-83-5P
817170-84-6P, 2-Benzyl-N-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-ylsulfonyl]propionamide 817170-85-7P, 2-Benzyl-3-[4-(2-fluorophenyl)piperazin-1-ylsulfonyl]-N-hydroxypropionamide 817170-86-8P, 2-Benzyl-3-[4-(2,4-difluorophenyl)piperazin-1-ylsulfonyl]-N-hydroxypropionamide 817170-87-9P, 2-Benzyl-N-hydroxy-3-(4-o-tolylpiperazin-1-ylsulfonyl)propionamide 817170-88-0P 817170-89-1P, 2-Benzyl-3-[4-(4-ethoxy-2-methylphenyl)piperazin-1-ylsulfonyl]-N-hydroxypropionamide 817170-90-4P, 2-Cyclopentyl-3-[4-(2,4-difluorophenyl)piperazin-1-ylsulfonyl]-N-hydroxypropionamide 817170-91-5P, N-Hydroxy-2-phenyl-3-(4-o-tolylpiperazin-1-ylsulfonyl)propionamide 817170-92-6P 817170-93-7P 817170-97-1P
817170-98-2P 817171-00-9P 817171-01-0P
817171-02-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (piperazinylsulfonyl)alkanoic acid amide derivs. useful as CD23 shedding inhibitors)

RN 817170-72-2 CAPLUS

CN Butanamide, N-hydroxy-3-methyl-2-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 817170-73-3 CAPLUS
CN Butanamide, 2-[[[4-(2-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-74-4 CAPLUS
CN Butanamide, 2-[[[4-(2,4-difluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-75-5 CAPLUS
CN Butanamide, 2-[[[4-(4-fluoro-2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-76-6 CAPLUS
CN Butanamide, 2-[[[4-(2,4-dimethylphenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-77-7 CAPLUS
CN Butanamide, 2-[[[4-(2,3-dimethylphenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-78-8 CAPLUS
CN Butanamide, N-hydroxy-2-[[[4-(2-methoxyphenyl)-1-piperazinyl]sulfonyl]methyl]-3-methyl- (CA INDEX NAME)



RN 817170-79-9 CAPLUS
CN Butanamide, 2-[[[4-(2-chlorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-80-2 CAPLUS
CN Butanamide, 2-[[[4-(2-ethylphenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-81-3 CAPLUS
CN Butanamide, 2-[[[4-[2-fluoro-4-(trifluoromethyl)phenyl]-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-82-4 CAPLUS
CN Butanamide, 2-[[[4-(4-ethoxy-2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 817170-83-5 CAPLUS

CN Butanamide, N-hydroxy-3-methyl-2-[[[4-[2-methyl-4-(trifluoromethoxy)phenyl]-1-piperazinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 817170-84-6 CAPLUS

CN Benzenepropanamide, N-hydroxy-α-[[[4-(2-methoxyphenyl)-1-piperazinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 817170-85-7 CAPLUS

CN Benzenepropanamide, α-[[[4-(2-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 817170-86-8 CAPLUS

CN Benzenepropanamide, α-[[[4-(2,4-difluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 817170-87-9 CAPLUS

CN Benzenepropanamide, N-hydroxy-α-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 817170-88-0 CAPLUS

CN Benzenepropanamide, N-hydroxy-α-[[[4-[2-methyl-4-(trifluoromethoxy)phenyl]-1-piperazinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 817170-89-1 CAPLUS

CN Benzenepropanamide, α-[[[4-(4-ethoxy-2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 817170-90-4 CAPLUS

CN Cyclopentaneacetamide, α-[[[4-(2,4-difluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 817170-91-5 CAPLUS
CN Benzeneacetamide, N-hydroxy-α-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 817170-92-6 CAPLUS
CN 2H-Pyran-4-acetamide, tetrahydro-N-hydroxy-α-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 817170-93-7 CAPLUS
CN Butanamide, N-hydroxy-3-methyl-2-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 817170-97-1 CAPLUS
CN Benzenepropanamide, α-[[[4-(2,4-difluorophenyl)-1-piperazinyl]sulfonyl]methyl]-3,4-difluoro-N-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 817170-98-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R)-2-(hydroxyamino)-1-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 817171-00-9 CAPLUS
CN 4-Piperidineacetamide, N-hydroxy-α-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-, (αR)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 817170-99-3
CMF C19 H30 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 817171-01-0 CAPLUS
CN 4-Piperidineacetamide, 1-ethyl-N-hydroxy-α-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 817171-02-1 CAPLUS
CN 4-Piperidineacetamide, N-hydroxy-1-methyl-α-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:376821 CAPLUS Full-text
DOCUMENT NUMBER: 138:368756
TITLE: Preparation of N-hydroxy pyrrolidinones and related novel MMP-12 metalloproteinase inhibitors
INVENTOR(S): Eriksson, Anders; Lepistoe, Matti; Lundkvist, Michael; Munck Af Rosenschoeld, Magnus; Stenvall, Kristina; Zlatoidsky, Pavol
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040098	A1	20030515	WO 2002-SE2023	20021106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002347727	A1	20030519	AU 2002-347727	20021106
EP 1444202	A1	20040811	EP 2002-783926	20021106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005515976	T	20050602	JP 2003-542144	20021106
US 2005026990	A1	20050203	US 2004-494645	20040505
US 7132434	B2	20061107		

PRIORITY APPLN. INFO.:	SE 2001-3710	A	20011107
	WO 2002-SE2023	W	20021106

OTHER SOURCE(S): MARPAT 138:368756
GI



I

AB N-hydroxy pyrrolidinones and related compds. (shown as I; variables defined below; e.g. 3-[[4-(4-fluorophenyl)piperazin-1-ylsulfonyl]methyl]-1-hydroxypyrrolidin-2-one) are useful as metalloproteinase inhibitors, especially as inhibitors of MMP12 (no data). Although the methods of preparation are not claimed, 34 example prepns. are included. For I: X = CO, CS or CR1R2; Z = SO2, SO2N(R3), N(R4)SO2, or N(R4)SO2N(R3); n is 0 or 1; m is 0 or 1; R1 and R2 = H or C1-6 alkyl; R3 and R4 = H, C1-6 alkyl, phenyl-C1-6 alkyl, or heteroaryl-C1-6 alkyl. R5 is a mono, di- or tricyclic group comprising 1-3 ring structures each of ≤7 ring atoms = cycloalkyl, aryl, heterocycloalkyl or heteroaryl, with each ring structure being independently optionally substituted by ≥1 halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, thiolo, C1-6 thioloalkyl, C1-6 thiolo-haloalkyl, sulfono, C1-6 sulfonoalkyl, C1-6 sulfonohaloalkyl, aminosulfonyl, sulfoxy, C1-6 sulfoxyalkyl, amino, cyanoamino, hydrazine, C1-6 aminoalkyl, aminocarbonylamine, methylsulfonamine, acetamido, N-(C1-3 alkyl)acetamido, carboxamide, N(C1-3 alkyl)carboxamide, N,N-di(C1-3 alkyl)carbamate, cyano, C1-6 cyanoalkyl, hydroxy, nitro, nitroso, formyl, N-methylformamide, Me formate, Et formate, acetyl, acetoxy; when R5 is a di- or tricyclic group, each ring structure is joined to the next ring structure by a direct bond, by -O-, by -S-, by -N-, by C1-3-alkyl, by C1-3 heteroalkyl, or is fused to the next ring structure.

IT 524045-10-1P, N-tert-Butoxy-2-[[4-(4-fluorophenyl)piperazin-1-ylsulfonyl]methyl]-4-hydroxybutyramide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-hydroxy pyrrolidinones and related novel MMP-12 metalloproteinase inhibitors)

RN 524045-10-1 CAPLUS

CN Butanamide, N-(1,1-dimethylethoxy)-2-[[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:851145 CAPLUS Full-text
DOCUMENT NUMBER: 136:6007
TITLE: Preparation of hydroxamic acid derivatives
INVENTOR(S): Hannah, Duncan Robert; Dyke, Hazel Joan; Sharpe,

Andrew; Baxter, Andrew Douglas
PATENT ASSIGNEE(S): Darwin Discovery Limited, UK
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087870	A1	20011122	WO 2001-GB2151	20010515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2409035	A1	20011122	CA 2001-2409035	20010515
US 2002037900	A1	20020328	US 2001-858106	20010515
US 6809100	B2	20041026		
EP 1282614	A1	20030212	EP 2001-931847	20010515
EP 1282614	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533521	T	20031111	JP 2001-584266	20010515
AT 254118	T	20031115	AT 2001-931847	20010515
ES 2208595	T3	20040616	ES 2001-931847	20010515
AU 778368	B2	20041202	AU 2001-58540	20010515
US 2003216404	A1	20031120	US 2003-460894	20030612
US 6787536	B2	20040907		
US 2004266764	A1	20041230	US 2004-902753	20040729

PRIORITY APPLN. INFO.:		
GB 2000-11721	A	20000515
GB 2000-29393	A	20001201
US 2001-858106	A1	20010515
WO 2001-GB2151	W	20010515
US 2003-460894	A1	20030612

OTHER SOURCE(S): MARPAT 136:6007
GI



I

AB The title compds. DBXASO2CH2CR2R3CONHOH [R2 = H, alkyl, aryl, etc.; R3 = H, alkyl; or R2, R3 and the carbon atom to which they are attached together represent (un)substituted carbocyclic or heterocyclic ring; A =

(un)substituted heterocyclic ring (attached to SO2 through a nitrogen atom); B = (un)substituted (hetero)aryl; D = (un)substituted (hetero)aryl, heterocyclic ring (attached through a carbon atom); provided that B and D are not both Ph] which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes (no biol. data given), and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers, were prepared E.g., a multi-step synthesis of I was given.

IT 374930-62-8P 374930-64-0P 374930-67-3P
374930-69-5P 374930-70-8P 374930-72-0P
374930-73-1P 374930-74-2P 374930-75-3P
374930-77-5P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acid derivs.)

RN 374930-62-8 CAPLUS

CN Butanamide, 2-[[[4-[4-(2-furanyl)phenyl]-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 374930-64-0 CAPLUS

CN Butanamide, N-hydroxy-3-methyl-2-[[[4-[4-(3-pyridinyl)phenyl]-1-piperazinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 374930-67-3 CAPLUS

CN Butanamide, 2-[[[4-[5-(4-fluorophenyl)-2-pyrimidinyl]-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 374930-69-5 CAPLUS
CN Butanamide, 2-[[[4-[5-(4-chlorophenyl)-2-pyridinyl]-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 374930-70-8 CAPLUS
CN Butanamide, 2-[[[4-[5-(4-fluorophenyl)-2-pyridinyl]-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 374930-72-0 CAPLUS
CN Butanamide, N-hydroxy-3-methyl-2-[[[4-[5-(3-pyridinyl)-2-pyrimidinyl]-1-piperazinyl]sulfonyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 374930-73-1 CAPLUS
CN Butanamide, 2-[[[4-[5-(4-cyanophenyl)-2-pyrimidinyl]-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 374930-74-2 CAPLUS
CN Butanamide, 2-[[[4-[5-(3,4-dichlorophenyl)-2-pyrimidinyl]-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 374930-75-3 CAPLUS
CN Butanamide, N-hydroxy-3-methyl-2-[[[4-[5-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]-1-piperazinyl]sulfonyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 374930-77-5 CAPLUS
CN Butanamide, 2-[[[4-[5-(4-chlorophenyl)-2-pyrimidinyl]-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:636067 CAPLUS Full-text
DOCUMENT NUMBER: 135:195577
TITLE: Preparation of arylpiperazines and arylpiperidines as metalloproteinase inhibiting agents
INVENTOR(S): Barlaam, Bernard Christophe; Dowell, Robert Ian; Newcombe, Nicholas John; Tucker, Howard; Waterson, David
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062751	A1	20010830	WO 2001-GB616	20010215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2396971	A1	20010830	CA 2001-2396971	20010215
EP 1261595	A1	20021204	EP 2001-905883	20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008500	A	20030429	BR 2001-8500	20010215
JP 2003524008	T	20030812	JP 2001-562533	20010215
ZA 2002005845	A	20031022	ZA 2002-5845	20020722
NO 2002003951	A	20020820	NO 2002-3951	20020820
MX 2002PA08112	A	20021129	MX 2002-PA8112	20020820
US 2003139419	A1	20030724	US 2002-204389	20020927
PRIORITY APPLN. INFO.:			EP 2000-400469 A	20000221
			WO 2001-GB616 W	20010215

OTHER SOURCE(S): MARPAT 135:195577

GI



I

AB The title compds. [I; B = (un)substituted Ph, 2-pyridyl, 2-pyridyloxy, 4-pyrimidinyl; X = C, N; R1 = (trimethyl-1-hydantoin)alkyl, (un)substituted Ph, phenylalkyl, etc.], useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13, were prepared E.g., a 5-step synthesis of I [B = 4-FC6H4; X = CH; R1 = CH2Ph] was given.

IT 357187-72-5P 357187-73-6P 357187-74-7P
357187-75-8P 357187-76-9P 357187-77-0P
357187-78-1P 357187-79-2P 357187-80-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpiperazines and arylpiperidines as metalloproteinase inhibiting agents)

RN 357187-72-5 CAPLUS

CN Benzenepropanamide, α-[[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 357187-73-6 CAPLUS

CN Benzenebutanamide, α-[[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 357187-74-7 CAPLUS

CN Benzeneacetamide, α-[[[4-(5-chloro-2-pyridinyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 357187-75-8 CAPLUS

CN Benzenebutanamide, α-[[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-γ-methyl- (CA INDEX NAME)



RN 357187-76-9 CAPLUS

CN Benzenepropanamide, 4-chloro-α-[[[4-(5-chloro-2-pyridinyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 357187-77-0 CAPLUS

CN Benzenebutanamide, α-[[[4-(5-chloro-2-pyridinyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 357187-78-1 CAPLUS

CN Benzeneacetamide, 4-chloro-α-[[[4-(5-chloro-2-pyridinyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 357187-79-2 CAPLUS

CN Benzeneacetamide, 3,4-dichloro-α-[[[4-(5-chloro-2-pyridinyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 357187-80-5 CAPLUS

CN 2-Pyrimidinepentanamide, α-[[[4-(5-chloro-2-pyridinyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



IT 357187-86-1P 357187-92-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylpiperazines and arylpiperidines as metalloproteinase inhibiting agents)

RN 357187-86-1 CAPLUS

CN Benzenepropanamide, α-[[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-(phenylmethoxy)- (CA INDEX NAME)



RN 357187-92-9 CAPLUS

CN Benzenebutanamide, α-[[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-γ-methyl-N-(phenylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2000:161258 CAPLUS Full-text
DOCUMENT NUMBER:	132:207849
TITLE:	Preparation of arylpiperazines as metalloproteinase inhibiting agents (MMP)
INVENTOR(S):	Barlaam, Bernard Christophe; Newcombe, Nicholas John; Tucker, Howard; Waterson, David
PATENT ASSIGNEE(S):	Zeneca Limited, UK; Zeneca-Pharma Sa
SOURCE:	PCT Int. Appl., 82 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012478	A1	20000309	WO 1999-GB2801	19990825
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339761	A1	20000309	CA 1999-2339761	19990825
AU 9955247	A	20000321	AU 1999-55247	19990825
AU 764367	B2	20030814		
BR 9913255	A	20010522	BR 1999-13255	19990825
EP 1109787	A1	20010627	EP 1999-941751	19990825
EP 1109787	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200100605	T2	20010821	TR 2001-605	19990825
HU 2001003344	A2	20020228	HU 2001-3344	19990825
HU 2001003344	A3	20020328		
EE 200100106	A	20020617	EE 2001-106	19990825
JP 2002523493	T	20020730	JP 2000-567511	19990825
NZ 509730	A	20030530	NZ 1999-509730	19990825
RU 2220967	C2	20040110	RU 2001-108591	19990825
NZ 524921	A	20041029	NZ 1999-524921	19990825
AT 326448	T	20060615	AT 1999-941751	19990825
PT 1109787	T	20060929	PT 1999-941751	19990825
ES 2263284	T3	20061201	ES 1999-941751	19990825
TW 240722	B	20051001	TW 1999-88114833	19990830
ZA 2001001231	A	20020513	ZA 2001-1231	20010213
MX 2001PA01847	A	20020408	MX 2001-PA1847	20010220
US 6734184	B1	20040511	US 2001-763709	20010226
KR 771454	B1	20071031	KR 2001-702457	20010226
NO 2001001023	A	20010425	NO 2001-1023	20010228
NO 321478	B1	20060515		
BG 105369	A	20011231	BG 2001-105369	20010322
HK 1036060	A1	20061027	HK 2001-106732	20010924
AU 2003262101	A1	20031218	AU 2003-262101	20031112
US 2004171641	A1	20040902	US 2004-787775	20040226

PRIORITY APPLN. INFO.:			
	EP 1998-402144	A	19980831
	EP 1999-401351	A	19990604
	WO 1999-GB2801	W	19990825
	US 2001-763709	A1	20010226

OTHER SOURCE(S): MARPAT 132:207849
GI



I



II

AB The title compds. [I; B = monocyclic or bicyclic alkyl, aryl, etc.; R3 = H, halo, NO2. etc.; n = 1-3; P = (CH2)n (wherein n = 0-2), alkene, alkyne, etc.; A = (un)substituted 5-7 membered aliphatic ring; X1, X2 = N, C, where a ring substituent on ring A is a oxo group that is preferably adjacent a ring N atom; Y = SO2, CO; Z = CONHOH, Y = CO and Q = CR6R7, CR6R7CH2, NR6, NR6CH2 (wherein R6 = H, alkyl, aralkyl, etc.; R7 = H, alkyl; R7 together with R6 forms a carbocyclic or heterocyclic spiro 5-7 membered ring, the latter containing at least one heteroatom selected from N, O, S); Z = CONHOH, Y = SO2 and Q = CR6R7, CR6R7CH2; Z = N(OH)CHO and Q = CHR6, CHR6CH2, NR6CH2; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.], useful as metalloproteinase inhibitors (no data), especially as inhibitors of MMP 13, in treating arthritis and atherosclerosis, were prepared E.g., a multi-step synthesis of the title piperazine II was given. Compds. I are effective at 0.5-30 mg/kg/day.

IT 260438-46-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpiperazines as metalloproteinase inhibiting agents (MMP))

RN 260438-46-8 CAPLUS

CN Pentanamide, 2-[[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-N-hydroxy-4-methyl- (CA INDEX NAME)



IT 260441-20-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylpiperazines as metalloproteinase inhibiting agents (MMP))

RN 260441-20-1 CAPLUS

CN Pentanamide, N-[(2,4-dimethoxyphenyl)methoxy]-2-[[[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl]methyl]-4-methyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y'
'Y'' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> d his

(FILE 'HOME' ENTERED AT 16:59:22 ON 06 MAR 2008)

FILE 'REGISTRY' ENTERED AT 16:59:29 ON 06 MAR 2008
L1 STRUCTURE UPLOADED
L2 52 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:59:53 ON 06 MAR 2008
L3 5 S L2 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	29.65	208.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

STN INTERNATIONAL LOGOFF AT 17:03:03 ON 06 MAR 2008